Formulation of small activating RNA into lipidoid nanoparticles inhibits xenograft prostate tumor growth by inducing p21 expression

Keyphrases

• Antitumor Activity 25%
• Cancer Xenograft 25%
• Chemical Modification 25%
• Cip1 25%
• Delivery Vehicle 25%
• Double-stranded RNA 50%
• Duplex 25%
• Encapsulated Nanoparticles 25%
• Gene Expression 100%
• In Vivo Delivery 25%
• Intratumoral Injection 25%
• Lipidoid Nanoparticle 100%
• Lipidoids 75%
• Medicinal Properties 25%
• Nanoparticle Formulation 25%
• Novel Delivery 25%
• Nude Mice 25%
• P21 Expression 100%
• P21Cip1 25%
• Promoter Sequence 25%
• Prostate Cancer 25%
• Prostate Tumor 25%
• Prostate Tumor Growth 100%
• RNA Activation (RNAa) 100%
• RNA Interference 50%
• Small Activating RNA (saRNA) 100%
• Therapeutic Approaches 25%
• Therapeutic Potential 25%
• Tumor Suppressor 25%
• Tumor Xenograft 25%
• Xenograft 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Antitumor Activity 50%
• Disease 50%
• Double Stranded RNA 50%
• Nanoparticle 100%
• Nude Mouse 50%
• Prostate Cancer 50%
• Prostate Tumor 100%
• Tumor Growth 100%
• Tumor Suppressor Protein 50%